JP7837333B2 - Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート - Google Patents

Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート

Info

Publication number
JP7837333B2
JP7837333B2 JP2023531536A JP2023531536A JP7837333B2 JP 7837333 B2 JP7837333 B2 JP 7837333B2 JP 2023531536 A JP2023531536 A JP 2023531536A JP 2023531536 A JP2023531536 A JP 2023531536A JP 7837333 B2 JP7837333 B2 JP 7837333B2
Authority
JP
Japan
Prior art keywords
optionally substituted
conjugate according
independently
hydrogel conjugate
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023531536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550784A (ja
Inventor
エル シュナイダー，エリック
アール ハーン，ブライアン
ブイ サンティ，ダニエル
Original Assignee
プロリンクス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロリンクス エルエルシー filed Critical プロリンクス エルエルシー
Publication of JP2023550784A publication Critical patent/JP2023550784A/ja
Priority to JP2025151940A priority Critical patent/JP2025176137A/ja
Application granted granted Critical
Publication of JP7837333B2 publication Critical patent/JP7837333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023531536A 2020-11-25 2021-11-24 Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート Active JP7837333B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025151940A JP2025176137A (ja) 2020-11-25 2025-09-12 Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118568P 2020-11-25 2020-11-25
US63/118,568 2020-11-25
PCT/US2021/060763 WO2022115563A1 (en) 2020-11-25 2021-11-24 Extended release hydrogel conjugates of c-natriuretic peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025151940A Division JP2025176137A (ja) 2020-11-25 2025-09-12 Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート

Publications (2)

Publication Number Publication Date
JP2023550784A JP2023550784A (ja) 2023-12-05
JP7837333B2 true JP7837333B2 (ja) 2026-03-30

Family

ID=81754916

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023531536A Active JP7837333B2 (ja) 2020-11-25 2021-11-24 Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート
JP2025151940A Pending JP2025176137A (ja) 2020-11-25 2025-09-12 Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025151940A Pending JP2025176137A (ja) 2020-11-25 2025-09-12 Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート

Country Status (5)

Country Link
US (1) US20240041982A1 (https=)
EP (1) EP4251150A4 (https=)
JP (2) JP7837333B2 (https=)
CN (1) CN116635027A (https=)
WO (1) WO2022115563A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3236278A1 (en) 2021-12-13 2023-06-22 Kennett Sprogoe Effective doses of cnp conjugates
IL316466A (en) 2022-05-23 2024-12-01 Ascendis Pharma Growth Disorders As Liquid pharmaceutical formulations of cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508350A (ja) 1999-05-17 2003-03-04 コンジュケム，インコーポレーテッド 血液成分への結合体化を介するペプチダーゼ活性からの内因性治療用ペプチドの保護
WO2010033217A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of cd-np peptides
JP2012527244A (ja) 2009-05-20 2012-11-08 バイオマリン ファーマシューティカル インコーポレイテッド Ｃ型ナトリウム利尿ペプチドの変異体
JP2018502868A (ja) 2015-01-09 2018-02-01 アセンディス ファーマ グロース ディスオーダーズ エー／エス Ｃｎｐプロドラッグ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102109067B1 (ko) * 2011-09-07 2020-05-13 프로린크스 엘엘시 생분해성 교차결합을 가지는 하이드로젤
PL3386531T3 (pl) * 2015-12-08 2022-02-28 Biomarin Pharmaceutical Inc. Zastosowanie wariantów peptydu natriuretycznego typu c w leczeniu choroby zwyrodnieniowej stawów
IL259827B2 (en) * 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
LT3400019T (lt) * 2016-01-08 2022-12-12 Ascendis Pharma Growth Disorders A/S Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
NZ743487A (en) * 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
EP3922269A1 (en) * 2016-03-16 2021-12-15 Prolynx LLC Extended release conjugates of exenatide analogs
US11896671B2 (en) * 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
WO2020206358A1 (en) * 2019-04-05 2020-10-08 Prolynx Llc Improved conjugation linkers
KR20220004134A (ko) * 2019-04-26 2022-01-11 프로린크스 엘엘시 서방형 사이토카인 컨쥬게이트

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508350A (ja) 1999-05-17 2003-03-04 コンジュケム，インコーポレーテッド 血液成分への結合体化を介するペプチダーゼ活性からの内因性治療用ペプチドの保護
WO2010033217A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of cd-np peptides
JP2012527244A (ja) 2009-05-20 2012-11-08 バイオマリン ファーマシューティカル インコーポレイテッド Ｃ型ナトリウム利尿ペプチドの変異体
JP2018502868A (ja) 2015-01-09 2018-02-01 アセンディス ファーマ グロース ディスオーダーズ エー／エス Ｃｎｐプロドラッグ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Endocrinologie，1993年，Vol.132，pp.504-509

Also Published As

Publication number Publication date
EP4251150A4 (en) 2025-04-23
WO2022115563A1 (en) 2022-06-02
CN116635027A (zh) 2023-08-22
JP2023550784A (ja) 2023-12-05
JP2025176137A (ja) 2025-12-03
EP4251150A1 (en) 2023-10-04
US20240041982A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
JP7837333B2 (ja) Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート
US20210214412A1 (en) Glucose-responsive insulin
JP4463814B2 (ja) 新規のインスリン誘導体
EP1100522B1 (en) Pulmonary delivery of active agents
ES2390270T3 (es) Compuestos de GLP-1 unidos a polietilenglicol
EP2714070B1 (en) Long-acting glp-1/glucagon receptor agonists
AU2012360094B9 (en) FGF receptor (FGFR) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof
EP2018165B1 (fr) COMPOSES DIMERES AGONISTES DES RECEPTEURS DES FGFs
CN114478747B (zh) 一种人胰岛素或其类似物的酰化衍生物
EA003394B1 (ru) Нерастворимые инсулинсодержащие композиции, способы их получения, суспензионный препарат, способ лечения диабета и гипергликемии
JPH0469128B2 (https=)
JP2013545782A (ja) 長時間作用型インスリンと組み合わせた速効型インスリン
JP2003535106A (ja) グルコース検知性インスリン誘導体からの、インスリンのグルコース依存性放出
PT804479E (pt) Método para o tratamento de diabetes mellitus utilizando kgf
EP4442700A1 (en) Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
KR20160075665A (ko) 소마토스타틴 및 그 유사체의 컨쥬게이트
JP2018531217A (ja) エキセナチド修飾物及びその用途
JP2019536758A (ja) アシル化インスリン化合物
SK1702004A3 (sk) Farmaceutický prostriedok na liečenie diabetu, jeho použitie a súprava obsahujúca tento prostriedok
WO2019211842A1 (en) Long-acting human growth hormone-antagonists and methods of producing the same
US20190160152A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
US20240336658A1 (en) Cyclic peptide and preparation method and use thereof
US10914728B2 (en) Bioassay for insulin formulations
KR20080041661A (ko) 생체적합성 폴리머와 컨쥬게이트된 인간 성장 호르몬
WO1996031530A1 (en) Novel peptides and remedy for bone diseases containing the same as active ingredient

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260317

R150 Certificate of patent or registration of utility model

Ref document number: 7837333

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150